Howland Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.29M Sell
22,408
-118
-0.5% -$6.78K 0.05% 149
2026
Q1
$1.37M Hold
22,526
0.05% 138
2025
Q4
$1.22M Sell
22,526
-1,734
-7% -$83.4K 0.05% 141
2025
Q3
$1.09M Sell
24,260
-2,247
-8% -$105K 0.04% 154
2025
Q2
$1.23M Sell
26,507
-2,760
-9% -$135K 0.05% 145
2025
Q1
$1.78M Buy
29,267
+9,535
+48% +$556K 0.08% 119
2024
Q4
$1.12M Buy
19,732
+138
+0.7% +$7.71K 0.05% 146
2024
Q3
$1.01M Sell
19,594
-2,324
-11% -$109K 0.04% 151
2024
Q2
$910K Sell
21,918
-3,011
-12% -$135K 0.04% 148
2024
Q1
$1.35M Buy
24,929
+364
+1% +$18.5K 0.07% 122
2023
Q4
$1.26M Sell
24,565
-749
-3% -$39.3K 0.07% 126
2023
Q3
$1.47M Sell
25,314
-188
-0.7% -$11.5K 0.09% 113
2023
Q2
$1.63M Sell
25,502
-50
-0.2% -$3.35K 0.09% 105
2023
Q1
$1.77M Sell
25,552
-510
-2% -$36K 0.11% 101
2022
Q4
$1.88M Buy
26,062
+875
+3% +$66K 0.12% 98
2022
Q3
$1.79M Buy
25,187
+3,842
+18% +$279K 0.12% 94
2022
Q2
$1.66M Buy
21,345
+9,710
+83% +$740K 0.1% 98
2022
Q1
$850K Buy
11,635
+330
+3% +$22.2K 0.05% 117
2021
Q4
$705K Sell
11,305
-857
-7% -$50.3K 0.04% 137
2021
Q3
$720K Sell
12,162
-400
-3% -$26.3K 0.04% 137
2021
Q2
$839K Sell
12,562
-3,805
-23% -$248K 0.04% 133
2021
Q1
$1.03M Sell
16,367
-930
-5% -$57.9K 0.06% 118
2020
Q4
$1.07M Sell
17,297
-981
-5% -$60.3K 0.06% 109
2020
Q3
$1.1M Sell
18,278
-495
-3% -$29.8K 0.07% 102
2020
Q2
$1.1M Sell
18,773
-1,780
-9% -$106K 0.08% 103
2020
Q1
$1.15M Sell
20,553
-127,566
-86% -$7.8M 0.1% 99
2019
Q4
$9.51M Buy
148,119
+117,144
+378% +$6.71M 0.68% 51
2019
Q3
$1.57M Buy
30,975
+4,900
+19% +$230K 0.12% 94
2019
Q2
$1.18M Sell
26,075
-5,588
-18% -$260K 0.09% 104
2019
Q1
$1.51M Sell
31,663
-1,205
-4% -$60K 0.12% 90
2018
Q4
$1.71M Sell
32,868
-18,802
-36% -$1.01M 0.16% 84
2018
Q3
$3.21M Buy
51,670
+678
+1% +$40.2K 0.24% 79
2018
Q2
$2.82M Buy
50,992
+640
+1% +$34.6K 0.23% 82
2018
Q1
$3.19M Buy
50,352
+7,765
+18% +$500K 0.26% 77
2017
Q4
$2.61M Sell
42,587
-115
-0.3% -$7.19K 0.21% 82
2017
Q3
$2.72M Buy
42,702
+410
+1% +$23.9K 0.22% 81
2017
Q2
$2.36M Sell
42,292
-30
-0.1% -$1.63K 0.2% 84
2017
Q1
$2.3M Sell
42,322
-46
-0.1% -$2.52K 0.2% 84
2016
Q4
$2.48M Buy
42,368
+3,096
+8% +$169K 0.23% 80
2016
Q3
$2.12M Buy
39,272
+1,000
+3% +$64.2K 0.2% 81
2016
Q2
$2.81M Buy
38,272
+1,178
+3% +$83.2K 0.27% 71
2016
Q1
$2.37M Sell
37,094
-1,350
-4% -$85.1K 0.24% 73
2015
Q4
$2.65M Buy
38,444
+2,985
+8% +$197K 0.27% 75
2015
Q3
$2.1M Hold
35,459
0.23% 79
2015
Q2
$2.36M Hold
35,459
0.24% 82
2015
Q1
$2.29M Sell
35,459
-135
-0.4% -$8.45K 0.23% 82
2014
Q4
$2.1M Sell
35,594
-25
-0.1% -$1.41K 0.21% 82
2014
Q3
$1.82M Sell
35,619
-297
-0.8% -$14.8K 0.19% 86
2014
Q2
$1.74M Buy
35,916
+48
+0.1% +$2.37K 0.18% 88
2014
Q1
$1.86M Sell
35,868
-507
-1% -$27K 0.21% 86
2013
Q4
$1.93M Sell
36,375
-214
-0.6% -$10.9K 0.24% 83
2013
Q3
$1.69M Buy
36,589
+12,660
+53% +$556K 0.23% 84
2013
Q2
$1.07M Buy
+23,929
New +$1.04M 0.17% 84

Other funds holding BMY

Howland Capital Management's BMY Position: Q2 2026 in Review

Howland Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 0.52% in Q2 2026, selling an estimated $6.78K and leaving 22,408 shares worth $1.29M. The position accounts for 0.05% of the portfolio, ranked #149.

Howland Capital Management first reported a position in BMY in Q2 2013 and has held it in 53 quarters since. The position peaked at $9.51M in Q4 2019. 796 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Howland Capital Management held 22,408 shares of Bristol-Myers Squibb worth $1.29M as of Q2 2026.
  • Howland Capital Management sold 118 Bristol-Myers Squibb shares in Q2 2026, an estimated $6.78K.
  • Bristol-Myers Squibb made up 0.05% of Howland Capital Management's portfolio in Q2 2026, its #149 holding.
  • Howland Capital Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 53 quarters since.
  • Howland Capital Management's Bristol-Myers Squibb position peaked at $9.51M in Q4 2019.
  • 796 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Howland Capital Management's 13F filing for Q2 2026, filed 13 Jul 2026.